Fig. 2From: Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumorsSteady-state mean trough concentration (Ctrough) of chiauranib. Mean Ctrough after a continuous oral dose of 10, 20, 35, 50, and 65 mg chiauranib capsules once daily in patients throughout the treatment cycles were shownBack to article page